)
Visual22 Oct 2025
Epiroc's cash spent on M&A
Infant Bacterial Therapeutics (IBT) investor relations material
Infant Bacterial Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary20 Aug, 2025
Executive summary
Preparations for the launch of IBP-9414, a drug for preventing NEC in premature infants, are ongoing, with regulatory submissions to the FDA completed and review underway.
The FDA granted Breakthrough Therapy Designation to IBP-9414 in March 2025, recognizing its potential to reduce gastrointestinal-related mortality.
The company is restructuring, reducing clinical staff and reallocating resources to marketing and business development in anticipation of product launch.
Manufacturing validation is nearly complete, with the final analytical method expected to be validated by October 2025.
Financial highlights
Net sales were SEK 0 for both Q2 and the first half of 2025, unchanged from the previous year.
Operating loss for Q2 2025 was SEK -20.1 million, an improvement from SEK -44.3 million in Q2 2024; for H1 2025, operating loss was SEK -37.6 million, improved from SEK -74.1 million year-over-year.
Earnings per share before and after dilution were SEK -1.42 for Q2 2025 and SEK -2.67 for H1 2025, both improved from the prior year.
Cash flow for H1 2025 was SEK -43.9 million, compared to SEK -60.7 million in H1 2024.
Cash balance at June 30, 2025, was SEK 176.3 million, down from SEK 223.4 million at year-end 2024.
Outlook and guidance
The FDA review of IBP-9414 is ongoing, with initial feedback expected in September 2025; launch timing will be clarified after feedback.
Capital is considered sufficient to fund operations through the marketing authorization application process.
The company is focused on cautious spending and is actively preparing for commercialization, including hiring for business development.
When will IBT get FDA review timeline clarity?
How is IBT restructuring for IBP-9414 launch?
What is IBT's cash runway beyond market approval?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Infant Bacterial Therapeutics earnings date
Q3 202513 Nov, 2025
Next Infant Bacterial Therapeutics earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Infant Bacterial Therapeutics is a Sweden-based pharmaceutical company focused on developing microbiome-based treatments for diseases affecting premature infants and children. Its primary focus is on preventing necrotizing enterocolitis and other serious conditions using live bacterial therapies. Infant Bacterial Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the NASDAQ Stockholm.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage